Lupin to Divest its Stake in Kyowa to Unison for ~$525M

 Lupin to Divest its Stake in Kyowa to Unison for ~$525M

Lupin to Divest its Stake in Kyowa to Unison for ~$525M

Shots:

  • Lupin’s subsidiary Nanomi to sell its entire stake (99.82%) in Kyowa to Unison’s entity Plutus in an all-cash transaction for an enterprise value of ~$525.87M and will generate post-tax net cash inflow of ~$300M.  The transfer is expected to be completed in Mar’2020
  • The divestiture will strengthen Lupin’s balance sheet and its growth capital to support organic and inorganic initiatives, allowing it to focus on key markets
  • Kyowa in collaboration with Unison will provide various solutions beyond the pharmaceutical business by leveraging its strong position in CNS generics, longlisted and specialty products with Unison’s investments in healthcare, forming a leading CNS company

Click here, Click here to­ read full press release/ article | Ref: Lupin, Kyowa | Image: Business Standard

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post